Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comments on: Cost-effectiveness of DPYD genotyping prior to capecitabine administration for metastatic breast cancer.

Breast cancer research and treatment - 26 Jun 2026

Jayaswal Rajesh Prasad, Rana Anuj Kumar, Badyal Rama Kumari

Abstract excerpt

DPYD genotyping before capecitabine therapy represents a clinically actionable pharmacogenomic strategy to reduce avoidable fluoropyrimidine-related toxicity in metastatic breast cancer. Commenting on the cost-effectiveness analysis by Chiddarwar, Blaes and Kuntz, this correspondence supports the authors' findings while extending the discussion from economic value to implementation readiness. We propose that DPYD...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Capecitabine

Share to Cost-Benefit Analysis

Share to Dihydrouracil Dehydrogenase (NADP)

Share to Genotype

Share to Neoplasm Metastasis

Share to Pharmacogenetics

Source

Identifiers

PMID: 42360572
DOI: 10.1007/s10549-026-08016-1

Genes

DPYD

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comments on: Cost-effectiveness of DPYD genotyping prior to capecitabine administration for metastatic breast cancer.PMID 42360572Read ↗

Cost-effectiveness of DPYD genotyping prior to capecitabine administration for metastatic breast cancer.Semantic proximity Read ↗

Cost-Effectiveness of DPYD Genotyping Prior to Capecitabine Administration for Metastatic Breast CancerSemantic proximity Read ↗

A Guide for Implementing DPYD Genotyping for Systemic Fluoropyrimidines into Clinical PracticeSemantic proximity Read ↗

Response to the FDA Decision Regarding DPYD Testing Prior to Fluoropyrimidine Chemotherapy.Semantic proximity Read ↗

Importance of and Strategies for Implementing DPYD Testing to Prevent Severe Fluoropyrimidine Chemotherapy Toxicity in Health Care Systems.Semantic proximity Read ↗

Dihydropyrimidine Dehydrogenase Deficiency and Implementation of Upfront DPYD Genotyping.Semantic proximity Read ↗

Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy.Semantic proximity Read ↗

DPYD Genotyping in Patients Who Have Planned Cancer Treatment With Fluoropyrimidines: A Health Technology Assessment.Semantic proximity Read ↗

All You Need to Know About DPYD Genetic Testing for Patients Treated With Fluorouracil and Capecitabine: A Practitioner-Friendly GuideSemantic proximity Read ↗

Dihydropyrimidine Dehydrogenase Deficiency (DPYD) Genotyping-Guided Fluoropyrimidine-Based Adjuvant Chemotherapy for Breast Cancer. A Cost-Effectiveness AnalysisSemantic proximity Read ↗

New advances in DPYD genotype and risk of severe toxicity under capecitabine.Semantic proximity Read ↗

Addressing barriers to increased adoption of DPYD genotyping at a large multisite cancer center.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.